---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-22-000024"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2022-04-22T23:59:59+00:00"
generated_at: "2026-06-26T05:25:59.779764+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vallon Pharmaceuticals eliminates SVP role, hires Ladenburg for strategic review to maximize value

## Summary
- Effective April 19, 2022, eliminated Penny Toren's SVP Regulatory Affairs position; no disagreement or cause; 6-month severance.
- Engaged Ladenburg Thalmann to evaluate strategic alternatives including merger, business combination, or asset sale.
- Clinical-stage biopharma focused on abuse-deterrent ADHD drugs ADAIR and ADMIR; cash preservation via streamlining.
- No assurance any transaction will result; company will not disclose details unless a specific deal is reached.

## SEC filing metadata
- accession: 0001824293-22-000024
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2022-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000024/0001824293-22-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000024/ck00018242493-20220419.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-22-000024
- JSON: https://secwatch.observer/filing/0001824293-22-000024.json
- Plain text: https://secwatch.observer/filing/0001824293-22-000024.txt

## Key facts
- Executive change
  Penny S. Toren departed as Senior Vice President, Regulatory Affairs & Project Management at GRI Bio, Inc..
  - Action: position eliminated
  - Role: Senior Vice President, Regulatory Affairs & Project Management
  source text: On April 19, 2022, Penny S. Toren's position as Senior Vice President, Regulatory Affairs & Project Management of Vallon Pharmaceuticals, Inc. (the "Company") was eliminated, effective immediately, as part of the Company's effort to streamline its operations in order to preserve its capital and cash resources and not as the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices or in any way for cause.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000024/0001824293-22-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.